Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. Dermira is focused on delivering important new therapies to the millions of patients living with chronic skin conditions such as plaque psoriasis, primary axillary hyperhidrosis, and acne vulgaris. In addition to these lead programs, the Company is using their experience and insight to identify and develop additional leading-edge medical dermatology pre-clinical programs.
Foresite Capital first became investors in Dermira during a secondary public offering and we have been enthusiastic about their diversified business structure with both a commercial stage product and rich pipeline. The company is co-developing Cimzia in plaque psoriasis with UCB pharma, a multibillion total market opportunity. Dermira’s pipeline includes innovative treatments for hyperhidrosis and acne vulgaris, both of which have unique mechanisms of action and serve patient populations in need of new treatment options. If successfully advanced, we believe both products could generate several hundred million dollars in annual sales. Dermira recently acquired rights to Lebrikizumab, an IL-13 blocking antibody for the treatment of atopmic dermatitis. We believe this acquisition is highly synergistic with Dermira’s existing product portfolio and will allow the company to leverage their sales and commercial infrastructure in the dermatology space.